July 20, 2021 Eluminex Biosciences Expands Leadership Team and Receives Award 典晶生物宣布扩大高级管理层和荣获中国潜在独角兽企业称号
July 19, 2021 Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform 典晶生物获得珐博进生物合成角膜技术及重组III型人胶原蛋白平台独占许可权
November 27, 2020 Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A Financing Portfolio | 专注眼科创新药研发的典晶生物完成五千万美元A轮融资 (qq.com)
